Latest Oncology News

Idasanutlin Promotes Transient Expansion of TP53-Mutant Subclones in Polycythemia Vera

November 25th 2020

By Jessica Hergert

November 25, 2020 - The oral MDM2 antagonist idasanutlin was found to promote expansion of TP53-mutant subclones among patients with polycythemia vera.

Panelists Parse Out Answers to Key Questions in Hematologic Malignancies

November 25th 2020

By Jessica Hergert

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

By Shiruyeh Schokrpur, MD, PHD

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

New Strategies Enhance Care in mUC

November 25th 2020

By Guru P. Sonpavde, MD

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Nivolumab Approved in Europe for Advanced Esophageal Cancer

November 24th 2020

By Gina Mauro

November 24, 2020 - The European Commission has approved nivolumab for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma following prior fluoropyrimidine- and platinum-based combination chemotherapy.

Latest Oncology Videos

All Oncology News

Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST

November 23rd 2020

By Kristi Rosa

November 23, 2020 - Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23rd 2020

By Denise Myshko

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers

November 22nd 2020

By Caroline Seymour

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.

Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC

November 21st 2020

By Hayley Virgil

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC

November 21st 2020

By Kristi Rosa

November 21, 2020 - Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a significant improvement in overall survival and progression-free survival per Independent Radiographic Review Committee versus sorafenib in patients with advanced unresectable hepatocellular carcinoma.

Maintenance Niraparib, Given at Individualized Starting Dose, Improves PFS in Chinese Patients With Ovarian Cancer

November 21st 2020

By Gina Mauro

November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.

Atezolizumab/Nab-Paclitaxel Induces Clinically Meaningful OS Benefit in PD-L1+ Locally Advanced or Metastatic TNBC

November 20th 2020

By Hayley Virgil

The combination of atezolizumab and nab-paclitaxel led to a clinically meaningful overall survival benefit in treatment-naïve patients with locally advanced or metastatic triple-negative breast cancer who had PD-L1 expressing tumor-infiltrating immune cells.

Asian Patients With HR+, HER2- Breast Cancer Have Higher Risk of Recurrence, May Benefit From Additional Adjuvant Abemaciclib

November 20th 2020

By Kristi Rosa

November 20, 2020 - Patients from Asian countries with hormone receptor–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib.

Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC

November 20th 2020

By Hiroji Iwata, MD, PhD

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

Osimertinib Plus Chemotherapy Is Well Tolerated in Frontline EGFR+ NSCLC

November 20th 2020

By Jason Harris

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.

Blood-Based Methylation Assay Enables Early, Accurate Detection of Solid Tumors

November 20th 2020

By Caroline Seymour

The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.

ctDNA Predicts Outcome for Frontline Immunotherapy in Metastatic Melanoma, But Not Second Line

November 20th 2020

By Hayley Virgil

November 20, 2020 - Circulating tumor DNAhas been found to be a reliable indicator of outcomes to treatment with frontline immune checkpoint inhibitors in patients with metastatic melanoma, but not in the second-line setting.

Prognostic Identifiers for ES-SCLC Are Not Revealed in CASPIAN Subgroup Analysis

November 20th 2020

By Brittany Lovely

November 20, 2020 - Exploratory subgroup analysis of patients with extensive-stage small-cell lung cancer who derived a progression-free survival benefit with durvalumab plus platinum-based chemotherapy lasting longer than 12 months in the CASPIAN trial did not reveal any clinical characteristics that could serve as predictive factors for benefit with the monoclonal antibody.

FDA Grants Priority Review to Loncastuximab Tesirine for Relapsed/Refractory DLBCL

November 20th 2020

By Kristi Rosa

November 20, 2020 - The FDA has granted a priority review designation to a biologics license application for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Experts Examine Potential Biomarkers for Immunotherapy in Melanoma

November 20th 2020

By Hayley Virgil

The emergence of immunotherapy in the melanoma treatment landscape has shifted the management of the disease; however, no strategies are in place to appropriately stratify patients for these potentially life-saving agents.

See All News

x